as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 ET–1 04.

Date: May 3, 2002.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Philip Perkins, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7804, Bethesda, MD 20892. (301) 435–1718.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 CONC 04.

Date: May 13, 2002.

Time: 3 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Sharon K. Pulfer, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140, MSC 7804, Bethesda, MD 20892. (301) 435–1767.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 26, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–10920 Filed 5–1–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: 1,8 Naphthalimide Imidazo [4,5,1-de] Acridones With Anti-Tumor Activity

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in U.S. Patent Application 60/187,991 filed on March 7, 2000, entitled ''1,8 Naphthalimide Imidazo [4,5,1-*de*] Acridones with Anti-Tumor Activity,'' to Avalon Pharmaceuticals, having a place of business in Gaithersburg, MD. The aforementioned patent rights have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Wendy R. Sanhai, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; e-mail: *sanhaiw@od.nih.gov*; Telephone: (301) 496–7056, ext. 244; Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION: This invention relates to the general fields of pharmaceuticals and cancer chemotherapy, particularly to the areas of cytotoxic antitumor agents and DNA intercalating agents. The lead imidazoacridone compound which will be the target of development of the exclusive licensee is WMC79, a novel synthetic agent with high selectivity and potency against colon, pancreatic and hematopoietic tumors. WMC79 is a novel synthetic agent with very potent but highly selective activity against colon cancer, pancreatic cancer as well as hematopoietic tumors. Preliminary data show that WMC79 is very active against colon cancer and pancreatic cancer xenografted into nude mice and is very well tolerated at doses that produce a strong anti-tumor effect.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the development of a drug for human administration, having therapeutic and pharmaceutical uses as an anti-cancer agent.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 24, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–10926 Filed 5–1–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Treatment of Ocular Disease With Pigment Epithelium Derived Factor (PEDF) Protein Using Non-Gene Therapy Means

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in any or all of (a) U.S. patents 5,840,686 (11/24/1998) and 6,319,687 (11/20/2001), (b) U.S. patent applications 07/894,215 (06/04/1992, now abandoned), 07/952,796 (9/24/1992, now abandoned), 08/279,979 (7/25/1994, now abandoned), 08/377,710 (01/25/1995, now abandoned), 08/520,373 (8/29/1995) and 09/630,629 (8/1/2000), and (c) foreign applications corresponding to PCT Patent Applications (i) PCT/US93/05358 entitled ''Retinal Pigmented Epithelium Derived Neurotrophic Factor'', published as WO 93/24529 (12/9/1993) and (ii) PCT/US95/07201, entitled ''Pigment Epithelium-Derived Factor: Characterization, Genomic Organization and Sequence of the PEDF Gene'', published as WO 95/33480 (12/14/95) to EyeTech Pharmaceuticals, Incorporated of New York, New York.

The prospective exclusive license may be limited to the development of compositions and methods for the treatment of ocular disease based on the

protein PEDF utilizing delivery methods other than gene therapy. The grant of the exclusive license proposed does not supercede that previously announced in 62 FR 62781–62782, November 25, 1997.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to Susan S. Rucker, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3821; telephone: 301/496–7056 ext 245; fax: 301/402–0220. A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe and claim compositions based on the molecule known as Pigment Epithelium Derived Factor (PEDF) and methods for making and using those compositions. PEDF is also known as EPC–1 (early population doubling level cDNA–1; RJ Pignolo, et al. J Biol Chem. 268(12):8949–57 (Apr 25, 1993)) and SLED (Bouck, et al. WO 99/04806 (2/4/99)). These methods and compositions include the protein, as well as recombinant applications thereof based on the amino acid and nucleic acid sequences of PEDF. PEDF is a member of the serpin (serine protease inhibitor) superfamily of proteins but has not been shown to posses the serine protease inhibitory properties. *In vitro* studies have demonstrated that PEDF has properties beneficial to neuronal tissue (neuronal cell survival, gliastatic, and neurotrophic activity) and anti-angiogenic properties. These properties suggest that PEDF may be useful in compositions and methods for the treatment of ocular diseases such as age-related macular degeneration and diabetic retinopathy which may be related to angiogenesis and neuronal tissue properties or in the treatment of cancers.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.,* a completed ''Application for License to Public Health Service Inventions'') in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Any objections to the grant of the contemplated license must specifically and separately, if more than one Notice of Intent to Grant related to these patents and patent applications is being responded to, reference the particular Notice of Intent to Grant being responded to and address only the proposed grant as set forth in the particular Notice of Intent to grant (*i.e.,* an objection to the proposed grant as set forth in this Notice of Intent to Grant to EyeTech Pharmaceuticals, Incorporated will not be considered an objection to the proposed grant as set forth in the concurrently published Notice of Intent to Grant to GenVec, Incorporated). Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 35 U.S.C. 552.

Dated: April 24, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–10928 Filed 5–1–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Delivery of Pigment Epithelium Derived Factor (PEDF) To Treat Cancer by Gene Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in any or all of (a) U.S. patents 5,840,686 (11/24/1998) and 6,319,687 (11/20/2001), (b) U.S. patent applications 07/894,215 (06/04/1992, now abandoned), 07/952,796 (9/24/1992, now abandoned), 08/279,979 (7/25/1994, now abandoned), 08/377,710 (01/25/1995, now abandoned), 08/520,373 (8/29/1995) and 09/630,629 (8/1/2000), and (c) foreign applications corresponding to PCT Patent Applications (i) PCT/US93/05358 entitled ''Retinal Pigmented Epithelium Derived Neurotrophic Factor'', published as WO 93/24529 (12/9/1993) and (ii) PCT/US95/07201, entitled ''Pigment Epithelium-Derived Factor: Characterization, Genomic Organization and Sequence of the PEDF Gene'', published as WO 95/33480 (12/14/95) to GenVec, Incorporated of Gaithersburg, Maryland.

The prospective exclusive license may be limited to the development of compositions and methods utilizing viral vector based gene therapy for the delivery of PEDF in the treatment of cancer. The grant of the exclusive license proposed does not supercede that previously announced in 62 FR 62781–62782, November 25, 1997.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to Susan S. Rucker, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3821; telephone: 301/496–7056 ext 245; fax: 301/402–0220. A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe and claim compositions and methods that incorporate the molecule known as Pigment Epithelium Derived Factor (PEDF). PEDF is also known as EPC–1 (early population doubling level cDNA–1; RJ Pignolo, et al. J Biol Chem. 268(12): 8949–57 (Apr. 25, 1993)) and SLED (Bouck, et al. WO 99/04806 (2/4/99)). These methods and compositions incorporating the molecule PEDF include the protein, as well as recombinant applications thereof based on the amino acid and nucleic acid sequences, for the molecule. PEDF is a member of the serpin (serine protease inhibitor) superfamily of proteins but has not been shown to posses the serine protease inhibitory properties. *In vitro* studies have demonstrated that PEDF has properties beneficial to neuronal tissue (neuronal cell survival, gliastatic, and neurotrophic activity) and anti-angiogenic properties. These properties suggest that PEDF may be useful in compositions and methods for the